| Rank |
Clinical Trial |
PubWeight™‹?› |
|
1
|
Women's Health Initiative (WHI)
|
535.42
|
|
2
|
Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer (WHS)
|
275.13
|
|
3
|
Bogalusa Heart Study
|
270.69
|
|
4
|
Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
|
260.47
|
|
5
|
Action to Control Cardiovascular Risk in Diabetes (ACCORD) (ACCORD)
|
232.27
|
|
6
|
Phase III Study of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Squamous Cell Esophageal Cancer
|
188.42
|
|
7
|
Health Professionals Follow-up Study
|
182.50
|
|
8
|
Screening for Prostate Cancer in Older Patients (PLCO Screening Trial)
|
143.85
|
|
9
|
Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes
|
140.34
|
|
10
|
A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer (PROFILE 1001)
|
139.78
|
|
11
|
Sleep Heart Health Study (SHHS) Data Coordinating Center (SHHS)
|
134.17
|
|
12
|
A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
|
130.69
|
|
13
|
A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies (MDX1106-03)
|
129.29
|
|
14
|
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
|
126.55
|
|
15
|
Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)
|
125.72
|
|
16
|
Look AHEAD: Action for Health in Diabetes (LookAHEAD)
|
125.12
|
|
17
|
Nurses' Health Study (Cardiovascular Component)
|
119.07
|
|
18
|
Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints (ECLIPSE)
|
118.66
|
|
19
|
Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
|
118.61
|
|
20
|
Sequenced Treatment Alternatives to Relieve Depression (STAR*D)
|
114.81
|
|
21
|
Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV (Zinc-Finger)
|
114.69
|
|
22
|
THE PARTNER TRIAL: Placement of AoRTic TraNscathetER Valve Trial (PARTNER)
|
113.35
|
|
23
|
A Comparison of Two Ways to Manage Anti-HIV Treatment (The SMART Study)
|
112.12
|
|
24
|
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate
|
112.04
|
|
25
|
Whitehall II - Social and Occupational Influences On Health and Illness
|
109.94
|
|
26
|
JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events
|
101.57
|
|
27
|
Epidemiology of Diabetes Interventions and Complications (EDIC)
|
100.87
|
|
28
|
Phase 1 Dose Escalation Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Patients
|
97.42
|
|
29
|
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
|
96.24
|
|
30
|
Male Circumcision for HIV Prevention in Rakai, Uganda
|
95.47
|
|
31
|
Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001) (KEYNOTE-001)
|
95.31
|
|
32
|
Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
|
93.10
|
|
33
|
Long QT Syndrome-Population Genetics and Cardiac Studies (LQTS)
|
89.78
|
|
34
|
Family Blood Pressure Program - GenNet Network
|
89.38
|
|
35
|
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection
|
88.60
|
|
36
|
Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.
|
86.36
|
|
37
|
Diabetes Control and Complications Trial (DCCT)
|
86.00
|
|
38
|
Ocular Hypertension Treatment Study (OHTS) (OHTS)
|
85.99
|
|
39
|
Multiple Ascending Dose (MDX1105-01) (Anti-PDL1)
|
84.16
|
|
40
|
Preventing Sexual Transmission of HIV With Anti-HIV Drugs
|
84.02
|
|
41
|
Study of Immunotherapy to Treat Advanced Prostate Cancer
|
83.34
|
|
42
|
Tarceva Italian Lung Optimization tRial (TAILOR)
|
82.56
|
|
43
|
National Lung Screening Trial (NLST) Screening (NLST)
|
80.71
|
|
44
|
BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
|
80.60
|
|
45
|
Heritage Study--Genetics, Exercise and Risk Factors (HERITAGE)
|
80.33
|
|
46
|
Multidisciplinary Study of Right Ventricular Dysplasia
|
79.39
|
|
47
|
French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin (CUPIC)
|
79.25
|
|
48
|
A Phase 1 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors
|
77.14
|
|
49
|
Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
|
77.03
|
|
50
|
Carotid Revascularization Endarterectomy Versus Stenting Trial (CREST)
|
76.92
|
|
51
|
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)
|
74.16
|
|
52
|
Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes (BARI2D)
|
73.12
|
|
53
|
SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
|
72.74
|
|
54
|
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
|
72.53
|
|
55
|
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC (CheckMate057)
|
72.49
|
|
56
|
Thrombotic, Inflammatory & Gene Markers of CVD in Women
|
71.21
|
|
57
|
OGX-427 in Castration Resistant Prostate Cancer Patients
|
71.10
|
|
58
|
Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
|
71.07
|
|
59
|
Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment (HALT-C)
|
70.55
|
|
60
|
Examining the Genetic Factors That May Cause Chronic Obstructive Pulmonary Disease (COPD) (COPDGene)
|
69.98
|
|
61
|
Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)
|
69.88
|
|
62
|
Genetically Engineered Lymphocyte Therapy in Treating Patients With B-Cell Leukemia or Lymphoma That is Resistant or Refractory to Chemotherapy
|
69.61
|
|
63
|
A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome (PLATO)
|
68.80
|
|
64
|
Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
|
68.71
|
|
65
|
Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy (AFFIRM)
|
68.65
|
|
66
|
Family Blood Pressure Program - HyperGEN
|
68.11
|
|
67
|
Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial
|
67.93
|
|
68
|
Lifestyle Intervention in a General Population for Prevention of Ischaemic Heart Disease
|
67.90
|
|
69
|
A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer (CLEOPATRA) (CLEOPATRA)
|
67.85
|
|
70
|
Childhood Asthma Management Program (CAMP) Phases I (Trial), II (CAMPCS), III (CAMPCS/2), and IV (CAMPCS/3) (CAMP)
|
67.70
|
|
71
|
CArdiosphere-Derived aUtologous Stem CElls to Reverse ventricUlar dySfunction (CADUCEUS)
|
67.70
|
|
72
|
Phase I Biomarker Study (BMS-936558)
|
67.22
|
|
73
|
Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2
|
67.09
|
|
74
|
Diagnosis and Treatment of Sleep Apnea in Cerebrovascular Disease (Go To Sleep)
|
66.40
|
|
75
|
Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212
|
66.16
|
|
76
|
Cardiac Stem Cell Infusion in Patients With Ischemic CardiOmyopathy (SCIPIO) (SCIPIO)
|
65.89
|
|
77
|
Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects
|
65.63
|
|
78
|
Mechanisms Underlying Psychosocial Associations With Ischemic Heart Disease (Kuopio)
|
65.46
|
|
79
|
Safety Study in Subjects With Leber Congenital Amaurosis
|
64.75
|
|
80
|
Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
|
64.69
|
|
81
|
Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men
|
64.46
|
|
82
|
Study to Prevent Cartilage Damage Following Acute Knee Injury.
|
63.93
|
|
83
|
An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation
|
63.76
|
|
84
|
A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (SHARP)
|
63.65
|
|
85
|
Herpes Simplex Virus Type 2 (HSV-2) Suppression to Prevent HIV Transmission
|
63.63
|
|
86
|
I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY 2)
|
63.53
|
|
87
|
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer (Prospect)
|
63.19
|
|
88
|
MADIT-CRT: Multicenter Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy (MADIT-CRT)
|
62.78
|
|
89
|
Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation (ARISTOTLE)
|
62.65
|
|
90
|
HIV Vaccine Trial in Thai Adults
|
62.58
|
|
91
|
Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition Within HIV-1 Discordant Couples (Partners PrEP)
|
62.00
|
|
92
|
Safety Study of CALAA-01 to Treat Solid Tumor Cancers
|
61.95
|
|
93
|
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer (PREVAIL)
|
61.93
|
|
94
|
Niacin Plus Statin to Prevent Vascular Events
|
61.69
|
|
95
|
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
|
61.46
|
|
96
|
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer
|
61.25
|
|
97
|
Cervical Intraepithelial Neoplasm (CIN) in Women (Gardasil)(V501-015)
|
60.65
|
|
98
|
Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18
|
60.55
|
|
99
|
SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries (SYNTAX)
|
60.31
|
|
100
|
A Study to Evaluate rhuFab V2 in Subjects With Minimally Classic or Occult Subfoveal Neovascular Macular Degeneration
|
60.31
|